UNSPSC 51434900: Combination antihypertensives

This classification denotes combination drugs that treat acute or chronic, persistently-high, systemic arterial blood pressure, or vascular hypertension, hence the term ANTIHYPERTENSIVES. Typical combination antihypertensive constituents are aliskiren, benazepril, candesartan, deserpidine, diltiazem, eprosartan, fosinopril, guanethidine, and hydralazine.

UNSPSC 51434900 Combination antihypertensives, a Class code, encompasses prescription medications and injectable pharmaceuticals that state and local governments procure for emergency medical services, health systems, and pharmacy benefit programs. Recent solicitations show purchasing driven by specific clinical needs: the City of Tampa's Fire Rescue ordered branded hypertensives and cardiac agents (Labetalol, Diltiazem, Adenosine, Epinephrine) for Advanced Life Support protocols; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) solicited generic multi-source pharmaceuticals and OTC products for statewide and regional health facility distribution. Issuing bodies range from municipal fire departments and state health agencies to cooperative purchasing vehicles that aggregate demand across multiple state and local jurisdictions. The mix reflects both transactional spot purchases for emergency medical supplies and strategic procurement frameworks designed to establish longer-term pricing agreements across networks of participating entities.

Activity concentrates in Florida, Texas, and Minnesota. The City of Tampa (Hillsborough County) issued an IFB for Advanced Life Support Medications with a due date of April 8, 2026, and an estimated contract value of $40,000, with a one-year initial term plus options to renew; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Texas HHS Commission posted an RFI on April 3, 2026, to gather market intelligence on direct-to-manufacturer pharmacy programs before formal competitive procurement. The Minnesota Department of Administration, administering MMCAP, issued an RFP due March 26, 2026, for generic pharmaceuticals to be distributed through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson) effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and the remainder on pricing format, EDI capability, compliance, and administrative fees. All three solicitations require vendor compliance with FDA standards, manufacturing certifications (cGMP, DSCSA), and comprehensive insurance coverage; expiration-date and shelf-life warranties are standard. Cooperative purchasing vehicles like MMCAP expand reach across multiple states and municipalities simultaneously.